All News
Filter News
Found 74,167 articles
-
Active Pharmaceutical Ingredients Market Size to Increase USD 416.15 Billion By 2033
4/15/2024
The global active pharmaceutical ingredients market size was evaluated at USD 237.48 billion in 2023 and it is expected to increase around USD 416.15 billion by 2033 with a CAGR of 5.77% from 2024 to 2033.
-
Structural Biology Market Experiencing Rapid Growth
4/15/2024
The global structural biology market is expanding rapidly worldwide, and between 2023 and 2032, hundreds of millions of dollars are expected to be generated in revenue altogether.
-
Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement
4/15/2024
Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH ) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
-
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
4/15/2024
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.
-
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
4/15/2024
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“ Kane ”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products, Inc. for US $8,000,000, plus net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000) (the “ Transaction ”).
-
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
4/15/2024
Applied Therapeutics, Inc. announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately.
-
InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
4/15/2024
InMode Ltd., a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511.
-
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
4/15/2024
First Wave BioPharma, Inc. announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will participate in the Longwood Healthcare Leaders Conference, which will be held April 29 - May 1, 2024 at The Ritz-Carlton in Key Biscayne, Florida.
-
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
4/15/2024
IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.
-
Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay
4/15/2024
Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.
-
American Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation Summit
4/15/2024
Vasomune Therapeutics, Inc. has been selected by the American Thoracic Society to showcase its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit (RIS).
-
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
4/15/2024
Daxor Corporation announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024.
-
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/15/2024
Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
-
After a years-long antitrust battle, the European Commission on Friday approved Illumina’s plans to divest Grail. However, Illumina said while there is “an agreement with the EC on specific divestment options” that “does not mean the method of divestment has been finalized.”
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
U.S. Biotechnology Market Size to Increase USD 1.79 Trillion by 2033
4/12/2024
According to Nova One Advisor, the U.S. Biotechnology market size was estimated at USD 552.49 billion in 2023
-
U.S. Gene Therapy Market Size, Share & Growth Report, 2033
4/12/2024
According to Nova One Advisor, the U.S. gene therapy market size was valued at USD 3.19 billion in 2023
-
Oncocyte Reports Full Year 2023 Financial ResultsConference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET
4/12/2024
Oncocyte Corporation, a precision diagnostics company, reported financial results for the year ended December 31, 2023.
-
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
4/12/2024
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced the latest research from its expansive neurology portfolio and pipeline to be presented at the 76th American Academy of Neurology (AAN) Annual Meeting, April 13-18, 2024, in Denver, Colorado, USA.
-
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
4/12/2024
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced two poster presentations on DAXXIFY® for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.